Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Alamar Biosciences has launched its NULISA DBS Extraction Kit, a significant advancement making ultra-high-sensitivity, multiplex proteomics feasible from home-collected fingerstick samples. This innovation directly addresses long-standing logistical hurdles, unlocking new possibilities for longitudinal, decentralized, and population-scale research essential for the earliest detection of diseases like Alzheimer's and inflammatory conditions. The challenge in leveraging dried blood spot (DBS) for advanced proteomics has been reliably recovering low-abundance protein signals from minute volumes across diverse collection devices. Alamar's kit, paired with its NULISA platform attomolar sensitivity, standardizes this extraction process. This move sharply contrasts with traditional venous blood draws, which are costly, invasive, and impractical for frequent, remote monitoring, thus democratizing access to crucial proteomic data. This development is poised to accelerate biomarker discovery and validation, transforming how neurodegenerative and inflammatory diseases are tracked and understood outside of major research centers. Researchers can now conduct continuous, non-invasive patient monitoring, potentially leading to earlier interventions and more personalized therapeutic strategies, cementing Alamar's position at the forefront of precision health.